Back to mobile site

Oppenheimer Removes $29 Price Target on Myriad Genetics (MYGN)

December 30, 2013 11:18 AM EST Send to a Friend
Oppenheimer keeps Myriad Genetics (Nasdaq: MYGN) at Market Perform, but removes its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login